Literature DB >> 18922937

Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.

Mark J Albers1, Robert Bok, Albert P Chen, Charles H Cunningham, Matt L Zierhut, Vickie Yi Zhang, Susan J Kohler, James Tropp, Ralph E Hurd, Yi-Fen Yen, Sarah J Nelson, Daniel B Vigneron, John Kurhanewicz.   

Abstract

An extraordinary new technique using hyperpolarized (13)C-labeled pyruvate and taking advantage of increased glycolysis in cancer has the potential to improve the way magnetic resonance imaging is used for detection and characterization of prostate cancer. The aim of this study was to quantify, for the first time, differences in hyperpolarized [1-(13)C] pyruvate and its metabolic products between the various histologic grades of prostate cancer using the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Fast spectroscopic imaging techniques were used to image lactate, alanine, and total hyperpolarized carbon (THC = lactate + pyruvate + alanine) from the entire abdomen of normal mice and TRAMP mice with low- and high-grade prostate tumors in 14 s. Within 1 week, the mice were dissected and the tumors were histologically analyzed. Hyperpolarized lactate SNR levels significantly increased (P < 0.05) with cancer development and progression (41 +/- 11, 74 +/- 17, and 154 +/- 24 in normal prostates, low-grade primary tumors, and high-grade primary tumors, respectively) and had a correlation coefficient of 0.95 with the histologic grade. In addition, there was minimal overlap in the lactate levels between the three groups with only one of the seven normal prostates overlapping with the low-grade primary tumors. The amount of THC, a possible measure of substrate uptake, and hyperpolarized alanine also increased with tumor grade but showed more overlap between the groups. In summary, elevated hyperpolarized lactate and potentially THC and alanine are noninvasive biomarkers of prostate cancer presence and histologic grade that could be used in future three-dimensional (13)C spectroscopic imaging studies of prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922937      PMCID: PMC2829248          DOI: 10.1158/0008-5472.CAN-08-0749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms.

Authors:  Liang Wang; Hedvig Hricak; Michael W Kattan; Hui-Ni Chen; Peter T Scardino; Kentaro Kuroiwa
Journal:  Radiology       Date:  2005-12-12       Impact factor: 11.105

Review 3.  High spatial resolution and speed in MRSI.

Authors:  S J Nelson; D B Vigneron; J Star-Lack; J Kurhanewicz
Journal:  NMR Biomed       Date:  1997-12       Impact factor: 4.044

4.  Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.

Authors:  Mark G Swanson; Andrew S Zektzer; Z Laura Tabatabai; Jeffry Simko; Samson Jarso; Kayvan R Keshari; Lars Schmitt; Peter R Carroll; Katsuto Shinohara; Daniel B Vigneron; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2006-06       Impact factor: 4.668

5.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Authors:  K K Yu; J Scheidler; H Hricak; D B Vigneron; C J Zaloudek; R G Males; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

6.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.

Authors:  A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

Review 7.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

Review 8.  Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging.

Authors:  Joan C Vilanova; Joaquim Barceló
Journal:  Abdom Imaging       Date:  2007 Mar-Apr

9.  The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme.

Authors:  R W Moreadith; A L Lehninger
Journal:  J Biol Chem       Date:  1984-05-25       Impact factor: 5.157

10.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

Authors:  Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle
Journal:  Nat Med       Date:  2007-10-28       Impact factor: 53.440

View more
  262 in total

1.  A method for simultaneous echo planar imaging of hyperpolarized ¹³C pyruvate and ¹³C lactate.

Authors:  Galen D Reed; Peder E Z Larson; Cornelius von Morze; Robert Bok; Michael Lustig; Adam B Kerr; John M Pauly; John Kurhanewicz; Daniel B Vigneron
Journal:  J Magn Reson       Date:  2012-02-24       Impact factor: 2.229

Review 2.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

3.  Metabolic imaging in the anesthetized rat brain using hyperpolarized [1-13C] pyruvate and [1-13C] ethyl pyruvate.

Authors:  Ralph E Hurd; Yi-Fen Yen; Dirk Mayer; Albert Chen; David Wilson; Susan Kohler; Robert Bok; Daniel Vigneron; John Kurhanewicz; James Tropp; Daniel Spielman; Adolf Pfefferbaum
Journal:  Magn Reson Med       Date:  2010-05       Impact factor: 4.668

4.  Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine.

Authors:  E Mazzio; K F A Soliman
Journal:  Neurotoxicology       Date:  2012-07-07       Impact factor: 4.294

5.  Separation of extra- and intracellular metabolites using hyperpolarized (13)C diffusion weighted MR.

Authors:  Bertram L Koelsch; Renuka Sriram; Kayvan R Keshari; Christine Leon Swisher; Mark Van Criekinge; Subramaniam Sukumar; Daniel B Vigneron; Zhen J Wang; Peder E Z Larson; John Kurhanewicz
Journal:  J Magn Reson       Date:  2016-07-09       Impact factor: 2.229

6.  Kinetic Analysis of Hepatic Metabolism Using Hyperpolarized Dihydroxyacetone.

Authors:  Alexander Kirpich; Mukundan Ragavan; James A Bankson; Lauren M McIntyre; Matthew E Merritt
Journal:  J Chem Inf Model       Date:  2019-01-15       Impact factor: 4.956

7.  Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI.

Authors:  Céline Taglang; David E Korenchan; Cornelius von Morze; Justin Yu; Chloé Najac; Sinan Wang; Joseph E Blecha; Sukumar Subramaniam; Robert Bok; Henry F VanBrocklin; Daniel B Vigneron; Sabrina M Ronen; Renuka Sriram; John Kurhanewicz; David M Wilson; Robert R Flavell
Journal:  Chem Commun (Camb)       Date:  2018-05-17       Impact factor: 6.222

8.  Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized (13)C magnetic resonance spectroscopic imaging.

Authors:  Jae Mo Park; Lawrence D Recht; Sonal Josan; Milton Merchant; Taichang Jang; Yi-Fen Yen; Ralph E Hurd; Daniel M Spielman; Dirk Mayer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

9.  Is higher lactate an indicator of tumor metastatic risk? A pilot MRS study using hyperpolarized (13)C-pyruvate.

Authors:  He N Xu; Stephen Kadlececk; Harrilla Profka; Jerry D Glickson; Rahim Rizi; Lin Z Li
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

10.  A regional bolus tracking and real-time B1 calibration method for hyperpolarized 13 C MRI.

Authors:  Shuyu Tang; Eugene Milshteyn; Galen Reed; Jeremy Gordon; Robert Bok; Xucheng Zhu; Zihan Zhu; Daniel B Vigneron; Peder E Z Larson
Journal:  Magn Reson Med       Date:  2018-09-18       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.